After completing this course, the reader will be able to:1. Describe the role of fibrinogen in coagulation and the inflammatory response and explain its importance in tumor proliferation, migration, and escape from immune regulation.2. Evaluate fibrinogen as a prognostic blood marker for survival and disease-free survival in patients with ovarian cancer.3. Incorporate fibrinogen testing as a relatively inexpensive, reliable, and available technique in the prognostic evaluation of ovarian cancer patients.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACTIntroduction. To evaluate pretherapeutic plasma fibrinogen levels as a prognostic parameter in patients with epithelial ovarian cancer (EOC). Materials and Methods. In the present multicenter study, pretherapeutic plasma fibrinogen levels were

BACKGROUND: To analyse the correlation between pre-treatment plasma fibrinogen levels and clinical -pathological parameters in patients with endometrial cancer and to assess the value of plasma fibrinogen as a prognostic parameter. METHODS: Within a retrospective multi-centre study, the records of 436 patients with endometrial cancer were reviewed and pre-treatment plasma fibrinogen levels were correlated with clinical -pathological parameters and patients' survival. RESULTS: The mean (s.d.) pre-treatment plasma fibrinogen level was 388.9 (102.4) mg per 100 ml. Higher plasma fibrinogen levels were associated with advanced tumour stage (FIGO I vs II vs III and IV, P ¼ 0.002), unfavourable histological subtype (endometrioid vs non-endometrioid histology, P ¼ 0.03), and higher patients' age (p67 years vs 467 years, P ¼ 0.04), but not with higher histological grade (G1 vs G2 vs G3, P ¼ 0.2). In a multivariate analysis, tumour stage (Po0.001 and Po0.001), histological grade (P ¼ 0.009 and P ¼ 0.002), patients' age (P ¼ 0.001 and Po0.001), and pre-treatment plasma fibrinogen levels (P ¼ 0.04 and P ¼ 0.02) were associated with disease-free and overall survival, respectively. CONCLUSION: Plasma fibrinogen levels can be used as an independent prognostic parameter for the disease-free and overall survival of patients with endometrial cancer.

No abstract

No abstract

Background: To date, there is no consensus on the utility of screening procedures for the early detection of endometrial cancer. The value of transvaginal ultrasound for screening of asymptomatic endometrial cancer has been discussed controversially. This study was conducted to evaluate whether asymptomatic patients with endometrial cancer have a better prognosis than symptomatic patients with endometrial cancer diagnosed after postmenopausal bleeding.

No abstract

No abstract

No abstract